Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 ResultsSeeking Alpha • 08/25/23
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsGlobeNewsWire • 08/14/23
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 03/16/23
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023GlobeNewsWire • 03/09/23
After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)Zacks Investment Research • 03/01/23
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 03/01/23
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis TrialGlobeNewsWire • 02/27/23
Down -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a TurnaroundZacks Investment Research • 02/13/23
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing DebtGlobeNewsWire • 12/16/22
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in ImmunologyGlobeNewsWire • 11/15/22
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/14/22
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare ConferenceGlobeNewsWire • 11/08/22